

# Peter Bossuyt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9109462/publications.pdf>

Version: 2024-02-01

113  
papers

6,208  
citations

168829

31  
h-index

81351

76  
g-index

115  
all docs

115  
docs citations

115  
times ranked

6042  
citing authors

#	ARTICLE	IF	CITATIONS
1	Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 208-217.	0.9	6
2	Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 689-699.	0.9	9
3	Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 199-206.	0.6	22
4	Is Also the Patient Ready for Switching from Intravenous to Subcutaneous Biologics?. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 515-516.	0.6	1
5	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 128-140.	3.7	45
6	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1321-1331.	0.9	5
7	Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2074-2082.	2.4	11
8	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 118-127.	3.7	49
9	Subtle Trap for the Inflammatory Bowel Disease Endoscopy Central Reader. <i>Gastroenterology</i> , 2022, , .	0.6	0
10	Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 439-445.	0.6	3
11	A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1511-1522.	0.6	6
12	High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1573-1582.e5.	2.4	20
13	Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1218-1225.e4.	2.4	10
14	Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 947-954.e2.	2.4	15
15	Variability in the Distribution of Histological Disease Activity in the Colon of Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 603-608.	0.6	6
16	Artificial intelligence and its impact on quality improvement in upper and lower gastrointestinal endoscopy. <i>Digestive Endoscopy</i> , 2021, 33, 242-253.	1.3	21
17	Computer-Aided Diagnosis With Monochromatic Light Endoscopy for Scoring Histologic Remission in Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 160, 23-25.	0.6	16
18	Tofacitinib and Subacute Pneumonitis: Don't Hold Your Breath. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 692-693.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Molecular detection of <i>Helicobacter pylori</i> and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE <i>Helicobacter pylori</i> assay. <i>Acta Clinica Belgica</i> , 2021, 76, 177-183.	0.5	15
20	Health Literacy and Quality of Life in Young Adults From The Belgian Crohn's Disease Registry Compared to Type 1 Diabetes Mellitus. <i>Frontiers in Pediatrics</i> , 2021, 9, 624416.	0.9	5
21	Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response. <i>GastroHep</i> , 2021, 3, 63-71.	0.3	8
22	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2021, 9, 451-460.	1.6	31
23	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 857-873.	8.2	56
24	Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. <i>American Journal of Gastroenterology</i> , 2021, 116, 134-141.	0.2	11
25	Scoring endoscopic disease activity in IBD: artificial intelligence sees more and better than we do. <i>Gut</i> , 2020, 69, 788-789.	6.1	17
26	Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2139-2141.e2.	2.4	17
27	Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 129-138.	1.9	87
28	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 637-646.e11.	2.4	67
29	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
30	Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. <i>Gut</i> , 2020, 69, 1778-1786.	6.1	79
31	Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1704-1718.	2.4	19
32	Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 680-685.	0.6	11
33	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
34	Letter to the Editor: Feasibility and Efficiency of an E-Health Preadmission Assessment System for Intravenous Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e11-e12.	0.9	1
35	Betting on quality indicators to improve inflammatory bowel disease surveillance outcome: All in or one to pick?. <i>Digestive Endoscopy</i> , 2020, 32, 523-525.	1.3	1
36	Endoscopic treatment of large symptomatic colon lipomas: A systematic review of efficacy and safety. <i>United European Gastroenterology Journal</i> , 2020, 8, 1147-1154.	1.6	20

#	ARTICLE	IF	CITATIONS
37	The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1062-1066.	0.8	8
38	Assessing Disease Activity in Ulcerative Colitis Using Artificial Intelligence: Can 'Equally Good' Be Seen as 'Better'? <i>Gastroenterology</i> , 2020, 159, 1625-1626.	0.6	10
39	Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. <i>Gut</i> , 2020, 69, 658-664.	6.1	21
40	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	0.6	126
41	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1037-1048.	0.6	55
42	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1562-1571.	0.9	27
43	Head-to-head trials in inflammatory bowel disease: past, present and future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 365-376.	8.2	37
44	Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 156-162.	0.9	24
45	P131 Effectiveness and safety of vedolizumab maintenance therapy for inflammatory bowel disease: findings from a Belgian registry. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S153-S154.	0.6	0
46	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 997-1006.e6.	0.6	86
47	OP25 Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S016-S018.	0.6	1
48	OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S024-S025.	0.6	12
49	DOP29 Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF, or conventional therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S041-S042.	0.6	4
50	DOP33 Long-term clinical efficacy of ustekinumab in refractory Crohn's disease : a multi-centre Belgian cohort study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S044-S045.	0.6	1
51	Upper gastrointestinal bleeding due to Gurriv's syndrome. <i>Digestive and Liver Disease</i> , 2019, 51, 1347.	0.4	0
52	Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. <i>BMC Medicine</i> , 2019, 17, 89.	2.3	40
53	Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1401-1409.	0.6	92
54	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1401-1409.	1.9	21

#	ARTICLE	IF	CITATIONS
55	P530 Ultra-proactive therapeutic drug monitoring incorporating infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during infliximab maintenance treatment. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S378-S378.	0.6	0
56	P564 Significant reduction of admission time at the IBD infusion unit by an e-health pre-admission assessment and order system for intravenous therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S396-S396.	0.6	0
57	PTH-077...De-escalating therapy in patients with crohn's disease receiving adalimumab: subgroup analysis of the calm study. , 2019, , .		0
58	P454 Prediction of endoscopic activity in patients with Crohn's disease: systematic review and external validation of published prediction models. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S338-S339.	0.6	0
59	P265 Pharmacokinetic and pharmacodynamic evaluation of radiological healing in Crohn's disease patients treated with Infliximab: a TAILORIX MRE substudy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S231-S231.	0.6	1
60	P194 Automated real-time endoscopic scoring based on machine learning in ulcerative colitis: Red Density reliability and responsiveness study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S187-S188.	0.6	0
61	N06 Patient-reported outcomes in daily clinical care of patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S559-S559.	0.6	0
62	Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 668-673.	0.8	9
63	Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 12-18.	0.6	47
64	The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 539-545.	0.8	12
65	Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1099-1105.	0.9	22
66	Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1343-1351.e1.	0.6	240
67	Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!. <i>Gastroenterology</i> , 2018, 154, 1196-1198.	0.6	2
68	Diffusion-weighted MRI in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 433-443.	3.7	21
69	Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 404-412.	3.7	56
70	European evidence-based guidelines on pancreatic cystic neoplasms. <i>Gut</i> , 2018, 67, 789-804.	6.1	878
71	Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 32-38.	0.6	33
72	Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. <i>United European Gastroenterology Journal</i> , 2018, 6, 439-445.	1.6	13

#	ARTICLE	IF	CITATIONS
73	Prime Time Was Yesterday for Patient-reported Outcomes in Daily Care of Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1839.	2.4	3
74	DOP003 Ustekinumab induces clinical and biological remission in biologic refractory Crohn's disease patients: A real-world belgian cohort study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S031-S032.	0.6	0
75	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease: A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2442-2451.	0.9	56
76	Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. <i>United European Gastroenterology Journal</i> , 2018, 6, 1117-1125.	1.6	48
77	436 - Automated Digital Calculation of Endoscopic Inflammation in Ulcerative Colitis: Results of the Red Density Study. <i>Gastroenterology</i> , 2018, 154, S-98-S-99.	0.6	2
78	Defining Endoscopic Remission in Ileocolonic Crohn's Disease: Let's Start from Scratch. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1245-1248.	0.6	24
79	Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 17-25.	1.0	10
80	Primetime for e-health in IBD?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 133-134.	8.2	9
81	Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus: A Multicenter Retrospective Study. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1605-1613.	0.9	27
82	Disease Course and Operative Risk after Diagnosis of Ileal Penetrating Crohn's Disease: A Cohort Study. <i>Gastroenterology</i> , 2017, 152, S1212.	0.6	0
83	Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm. <i>Gastroenterology</i> , 2017, 152, S155.	0.6	16
84	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2779-2789.	6.3	633
85	E-health in inflammatory bowel diseases: More challenges than opportunities?. <i>Digestive and Liver Disease</i> , 2017, 49, 1320-1326.	0.4	25
86	Management of patients with inflammatory bowel disease and spondyloarthritis. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1363-1374.	1.3	18
87	Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO). <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1584-1591.	0.9	7
88	Early Fibrostenosis in Crohn's Disease is Associated with Multiple Susceptibility Loci on ImmunoChip Analysis. <i>Gastroenterology</i> , 2017, 152, S982.	0.6	1
89	Development of the IBD Disk. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 333-340.	0.9	72
90	Tofacitinib Is the Right OCTAVE for Ulcerative Colitis. <i>Gastroenterology</i> , 2017, 153, 862-864.	0.6	8

#	ARTICLE	IF	CITATIONS
91	Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 101-111.	0.8	27
92	A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM 2017 ACG Governors Award for Excellence in Clinical Research. <i>American Journal of Gastroenterology</i> , 2017, 112, S321.	0.2	1
93	Paediatric Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 63, 253-258.	0.9	8
94	Su1809 Combining Anti-Inflammatory Treatment With Antiviral Treatment in Severe CMV Positive Ulcerative Colitis Does Not Affect Colectomy Rate: A Retrospective Multicenter Study. <i>Gastroenterology</i> , 2016, 150, S559.	0.6	0
95	692 Drug-Level Based Dosing Versus Symptom-Based Dose Adaptation in Patients With Crohn's Disease: A Prospective, Randomized Multicenter Study (TAILORIX). <i>Gastroenterology</i> , 2016, 150, S143.	0.6	16
96	Tu1218 Treatment of Zenker's Diverticulum Through a Flexible Endoscope With a Transparent Hood attached to the Tip and a Monopolar Forceps: Results of a Consecutive Series of 76 Patients. <i>Gastrointestinal Endoscopy</i> , 2016, 83, AB581.	0.5	0
97	Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1277-1290.	1.4	42
98	Su1814 The Need for Surgery in Stricturing Ileal CD Is Linked to Clinical and Imaging Factors But Independent of NOD2 Genotype. <i>Gastroenterology</i> , 2016, 150, S560.	0.6	2
99	Treat to Target in Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2016, 14, 61-72.	0.3	29
100	Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 514-521.e4.	2.4	116
101	Endoscopic removal of a transgastric eroded laparoscopic adjustable silicone gastric band. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 457-458.	0.5	1
102	Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1480-1486.e3.	2.4	55
103	The course of anaemia in children and adolescents with Crohn's disease included in a prospective registry. <i>International Journal of Colorectal Disease</i> , 2015, 30, 51-56.	1.0	2
104	Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 382-389.	0.6	7
105	Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2014, 2, 30-37.	1.6	118
106	P-092: The course of anaemia in children with Crohn's disease included in a prospective registry. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S429.	0.6	0
107	Buried bumper syndrome: single-step endoscopic management and replacement. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 336.	0.5	12
108	P495 Efficacy of switching to infliximab in Crohn's disease patients with loss of response to adalimumab. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S274.	0.6	0

#	ARTICLE	IF	CITATIONS
109	European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, 982-1018.	0.6	679
110	Wandering spleen on a 68Ga-DOTATOC-PET/CT scan. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 982-982.	3.3	5
111	Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. Journal of Crohn's and Colitis, 2010, 4, 194-198.	0.6	78
112	Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. Journal of Crohn's and Colitis, 2009, 3, 4-7.	0.6	114
113	Combination Immunomodulator and Antibiotic Treatment in Patients With Inflammatory Bowel Disease and Clostridium difficile Infection. Clinical Gastroenterology and Hepatology, 2009, 7, 981-987.	2.4	128